|
業務類別
|
Biotechnology |
|
業務概覽
|
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company. |
| 公司地址
| 275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065 |
| 電話號碼
| +1 650 206-4507 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.rezolutebio.com |
| 員工數量
| 58 |
| Mr. Daron Evans |
Chief Financial and Business Officer |
美元 480.00K |
21/10/2026 |
| Mr. Nevan Charles Elam, J.D. |
Acting Chairman of the Board and Chief Executive Officer |
美元 655.00K |
21/10/2026 |
| Dr. Brian Kenneth Roberts, M.D. |
Chief Medical Officer |
美元 512.16K |
21/10/2026 |
| Mr. Sunil Karnawat |
Chief Commercial Officer |
美元 415.63K |
21/10/2026 |
|
|
| Mr. Gil M. Labrucherie, C.F.A.,J.D. |
Independent Director |
21/10/2026 |
| Mr. Nevan Charles Elam, J.D. |
Acting Chairman of the Board and Chief Executive Officer |
21/10/2026 |
| Mr. Philippe Fauchet |
Independent Director |
21/10/2026 |
| Dr. Nerissa C. Kreher, M.D. |
Independent Director |
21/10/2026 |
| Dr. Wladimir Hogenhuis, M.D. |
Independent Director |
21/10/2026 |
| Mr. Erik Harris |
Independent Director |
21/10/2026 |
| Mr. Young-jin Kim |
Director |
21/10/2026 |
|
|
|
|